Niclosamide - SCAI Therapeutics
Alternative Names: SCAI-502Latest Information Update: 31 Mar 2023
Price :
$50 *
At a glance
- Originator SCAI Therapeutics
- Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
- Mechanism of Action Autophagy stimulants; Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown COVID 2019 infections
Most Recent Events
- 22 Feb 2023 Clinical trials in COVID-2019 infections (unspecified route) (SCAI Therapeutics pipeline, February 2023)